Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.40 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24587719 | 1.00 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24587010 | 0.98 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24587004 | 0.88 | MEN1 (0.49) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24587564 | 0.88 | MEN1 (0.49) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24587456 | 0.86 | MEN1 (0.50) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL29254327 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24587858 | 0.81 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AL3MBTL1CA12 | |
| SCHEMBL24586993 | 0.81 | EPHX2 (0.36) | ALDH1A1EPHX2GBA2 | |
| SCHEMBL25288877 | 0.80 | EPHX2 (0.52) | ALDH1A1MEN1KMT2AEPHX2 | |
| SCHEMBL24587012 | 0.79 | EPHX2 (0.36) | ALDH1A1MEN1KMT2AL3MBTL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4262818-A1 | NANOMATERIALS COMPRISING CARBONATES | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022140239-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140239-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | PHOSPHO1, CA13, SGMS2 | ALDH1A1 3544/4885MEN1 882/4885KMT2A 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.